Is Cosentyx Approved for All Types of Psoriasis?
No, Cosentyx (secukinumab) is not approved for all types of psoriasis. The FDA approves it specifically for moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy.[1] Plaque psoriasis accounts for about 80-90% of cases, but Cosentyx lacks approval for other forms like guttate, pustular, erythrodermic, or inverse psoriasis.
What Types of Psoriasis Does Cosentyx Treat?
Cosentyx targets IL-17A, a key cytokine in plaque psoriasis inflammation. Clinical trials (e.g., ERASURE, FIXTURE, CLEAR) showed it clears skin in 70-90% of moderate-to-severe plaque patients at week 12, with sustained results.[1][2] It does not have dedicated trials or labeling for non-plaque variants, where IL-17 pathways may differ.
Why Not Approved for Other Psoriasis Types?
Regulatory approval requires specific trial data. Pustular psoriasis, for example, involves distinct neutrophil-driven mechanisms, and Cosentyx trials excluded it. Recent data hint at off-label use, but no FDA nod yet—Japan approved it for generalized pustular psoriasis in 2022, unlike the US.[3]
How Does Cosentyx Compare to Drugs Approved for More Psoriasis Types?
| Drug | Plaque | Guttate | Pustular | Erythrodermic | Inverse |
|------|--------|---------|----------|---------------|---------|
| Cosentyx | Yes | No | No (US) | No | No |
| Tremfya (guselkumab) | Yes | No | No | No | No |
| Sotyktu (deucravacitinib) | Yes | Limited data | No | No | No |
| Spevigo (spesolimab) | No | No | Yes | No | No |
| Ilumya (tildrakizumab) | Yes | No | No | No | No |
Taltz (ixekizumab, another IL-17 inhibitor) mirrors Cosentyx's plaque focus but has some pustular data. Brodalumab covers plaque and has broader off-label use.[1][4]
Can Doctors Use Cosentyx Off-Label for Other Types?
Yes, off-label prescribing is legal for FDA-approved drugs. Small studies report success in pustular (50-70% improvement) and erythrodermic cases, but risks like infections rise without plaque-specific dosing data.[5] Patients often ask about this due to limited options.
What Are Common Patient Concerns with Cosentyx for Psoriasis?
Upper respiratory infections (15-20%), candidiasis (3-5%), and IBD flares (1%) top side effects. Long-term data (up to 5 years) show sustained efficacy with no new safety signals.[1][2] No black-box warnings, unlike some TNF inhibitors.
[1]: FDA Cosentyx Label
[2]: NEJM ERASURE Trial
[3]: Novartis Japan Approval
[4]: FDA Approvals Database
[5]: JAAD Pustular Review